Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline commences Benlysta vasculitis trial

GlaxoSmithKline commences Benlysta vasculitis trial

4th April 2013

GlaxoSmithKline has announced the commencement of a phase III clinical trial assessing the benefits of its approved lupus therapy Benlysta in a new indication.

The multicentre international study will evaluate the efficacy and safety of Benlysta plus azathioprine for the maintenance of remission in patients with a particular type of vasculitic disease called anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

A condition that sees blood vessels coming under attack from the body's own immune system leading to inflammation, vasculitis can result in disruption of blood flow and causes various levels of damage to different organs.

The effectiveness of Benlysta as a treatment for systemic lupus erythematosus has already been well-documented, with the drug having been approved for use against this condition in both the US and Europe since 2011.

It is hoped that it can prove to be a useful therapy option for ANCA-associated vasculitis, the most common type of primary systemic small-vessel vasculitis to occur in adults.

Last month, GlaxoSmithKline announced the submission of a European marketing authorisation application for albiglutide, a new diabetes therapy it intends to market under the brand name Eperzan.ADNFCR-8000103-ID-801566382-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.